Mirtazapin Krka (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Krka, is a NaSSA presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts as an antidepressant within the NaSSA class, targeting depressive disorders. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Depressive episodes associated with bipolar disorder: may be used as an adjunct to stabilize mood under specialist supervision. - Treatment‑resistant depression: considered when first‑line agents are ineffective, under careful clinical evaluation.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Seizures - Hepatic dysfunction - Severe allergic reactions (anaphylaxis)

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Monitor weight: watch for significant gain and metabolic changes. - Assess mood: watch for emergence of suicidal ideation, especially in early treatment. - Evaluate liver function: consider baseline tests in patients with hepatic disease. - Caution with CNS depressants: avoid excessive sedation when combined with alcohol or benzodiazepines. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels. - Anticholinergic drugs: additive anticholinergic burden.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect. - Carbamazepine: may reduce mirtazapine concentrations. - Warfarin: monitor INR for possible alteration. - Anticonvulsants: may affect seizure threshold. - Herbal supplements (e.g., St. John’s wort): could modify serotonergic activity.